International Centre for Medical Research, Dorset, UK.
Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
J Gen Intern Med. 2021 Jun;36(6):1726-1733. doi: 10.1007/s11606-020-06403-y. Epub 2021 Jan 19.
The aim of this study was to assess the effect of concomitant use of levothyroxine (LT4) and proton pump inhibitors (PPIs) on thyroid-stimulating hormone (TSH) levels in patients with primary hypothyroidism.
A systematic review of interventional and observational studies that compared the TSH levels before and after concomitant use of LT4 and PPI was performed. Articles published in English up to September 1, 2019, were included. PubMed, EMBASE, and Cochrane Library databases. Gray literature was also searched in repositories, websites OpenGrey and Google Scholar, and abstracts of major international congresses. Study quality was assessed with the Newcastle-Ottawa quality assessment scale for observational studies and the Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) tool was used.
Five thousand twelve discrete articles were identified. Following assessment and application of eligibility criteria, seven studies were included. There was a considerable heterogeneity among the included studies in design, sample size, inclusion and exclusion criteria, treatment regimen, and baseline demographics. Each of the included studies showed an increase in TSH levels following LT4 and PPI consumption, and in the majority of these, the increase was statistically significant.
The concomitant use of LT4 and PPI showed a significant increase in TSH concentration. However, given the small number of studies, further research is needed to clarify the interfering role of PPI on LT4 intestinal absorption.
CRD42020047084.
本研究旨在评估左甲状腺素(LT4)和质子泵抑制剂(PPIs)联合使用对原发性甲状腺功能减退症患者促甲状腺激素(TSH)水平的影响。
对比较 LT4 和 PPI 联合使用前后 TSH 水平的干预性和观察性研究进行了系统评价。纳入截至 2019 年 9 月 1 日发表的英文文章。检索了 PubMed、EMBASE 和 Cochrane Library 数据库。还在 OpenGrey 和 Google Scholar 网站等存储库以及主要国际大会的摘要中搜索了灰色文献。使用纽卡斯尔-渥太华质量评估量表对观察性研究进行了研究质量评估,使用非随机干预研究的风险偏倚(ROBINS-I)工具评估了研究的风险偏倚。
共确定了 5120 篇离散文章。经过评估和应用纳入标准,最终纳入了 7 项研究。纳入的研究在设计、样本量、纳入和排除标准、治疗方案以及基线人口统计学方面存在很大的异质性。纳入的每项研究均显示 LT4 和 PPI 联合使用后 TSH 水平升高,其中大多数研究的升高具有统计学意义。
LT4 和 PPI 的联合使用显著增加了 TSH 浓度。然而,由于研究数量较少,需要进一步研究来阐明 PPI 对 LT4 肠吸收的干扰作用。
PROSPERO 注册号:CRD42020047084。